Lee S H
Department of Pathology, Hospital of Saint Raphael, New Haven, Connecticut 06511.
Cancer. 1989 Oct 1;64(7):1461-6. doi: 10.1002/1097-0142(19891001)64:7<1461::aid-cncr2820640717>3.0.co;2-7.
Consecutive serial cryostat-frozen sections of 157 human mammary carcinomas and the uteri of six immature New Zealand white rabbits were stained histochemically for cytoplasmic estrogen receptor (ER) and nuclear ER by a fluorescent estrogen compound (Fluorocep Estrogen, Zeus Technologies, Inc., Raritan, NJ) and by a monoclonal antibody immunoperoxidase technique (ER-ICA, Abbott Laboratories, North Chicago, IL), respectively. The percentage of the ER-positive cells in the cancer cell population under observation was estimated and recorded. The results of the cytoplasmic ER assay were compared with those of the nuclear ER assay in each tumor; all cancers with less than 10% ER-positive cancer cells were grouped together as ER-negative tumors, the cancers with 30% or more ER-positive cancer cells as ER-positive tumors, and those with 10% to 29% ER-positive cancer cells as borderline positive. According to this manner of classification, 94% to 97% of the ER-positive mammary carcinomas diagnosed by one histochemical assay would have been identified as such by the other with no more than 10% difference in the ER-positive cell counts. The majority of ER-positive breast cancer cells and practically all of the luminal lining cells of the immature rabbit endometrium had coexistent cytoplasmic and nuclear ER. In the mammary cancers containing less than 30% ER-positive cancer cells, there was a greater (up to 20%) discrepancy in positive cell counts between the cytoplasmic ER assay and the nuclear ER assay. This discrepancy may be due to sampling errors of small clones of ER-positive cancer cells in two adjacent sections, difference in antigenic determinants between the cytoplasmic and the nuclear ER, and the binding sites in the nuclear ER being preoccupied by estrogen. The findings of this study appear to support the hypothesis that there are ER in the cytoplasm and the nucleus of the mammary carcinoma cells and the epithelial cells of the endometrium.
对157例人类乳腺癌以及6只未成熟新西兰白兔的子宫进行连续系列低温恒温器冷冻切片，分别采用荧光雌激素化合物（氟甲睾酮雌激素，宙斯技术公司，拉里坦，新泽西州）和单克隆抗体免疫过氧化物酶技术（雌激素受体免疫细胞化学分析，雅培实验室，北芝加哥，伊利诺伊州）对细胞质雌激素受体（ER）和细胞核ER进行组织化学染色。估计并记录观察到的癌细胞群体中ER阳性细胞的百分比。将每个肿瘤的细胞质ER检测结果与细胞核ER检测结果进行比较；所有ER阳性癌细胞少于10%的癌症归为ER阴性肿瘤，ER阳性癌细胞为30%或更多的癌症归为ER阳性肿瘤，ER阳性癌细胞为10%至29%的癌症归为临界阳性。按照这种分类方式，通过一种组织化学检测诊断为ER阳性的乳腺癌中，94%至97%通过另一种检测也会被确定为ER阳性，ER阳性细胞计数差异不超过10%。大多数ER阳性乳腺癌细胞以及未成熟兔子宫内膜的几乎所有腔面衬里细胞都同时存在细胞质和细胞核ER。在ER阳性癌细胞少于30%的乳腺癌中，细胞质ER检测和细胞核ER检测之间的阳性细胞计数差异更大（高达20%）。这种差异可能是由于相邻两个切片中ER阳性癌细胞小克隆的取样误差、细胞质和细胞核ER之间抗原决定簇的差异以及细胞核ER中的结合位点被雌激素占据。本研究结果似乎支持这样的假设，即乳腺癌细胞和子宫内膜上皮细胞的细胞质和细胞核中存在ER。
